Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02372253 · ClinicalTrials.gov registry record · Phase 2
Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes
A Phase 2 study of Type 1 Diabetes Mellitus, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT02372253 is a Phase 2 study of Type 1 Diabetes Mellitus that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 32 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02372253, a Phase 2 study of Type 1 Diabetes Mellitus, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this trial is to assess the efficacy and safety of using oral verapamil in subjects with recent onset T1D in order to downregulate TXNIP and enhance the patients' endogenous beta cell mass and insulin production. The objectives are therefore to assess parameters of beta cell survival (including new biomarkers), insulin production and glucose control and the feasibility of this approach and thereby provide the basis for future, larger/expanded, longer-term verapamil studies and the off-label use of this approved drug for Type 1 Diabetes (T1D).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Verapamil
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-02 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02372253
The ClinicalTrials.gov registry entry for NCT02372253 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (77% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02372253 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT02372253 about?
NCT02372253 is a clinical study titled "Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes". The overall purpose of this trial is to assess the efficacy and safety of using oral verapamil in subjects with recent onset T1D in order to downregulate TXNIP and enhance the patients' endogenous beta cell mass and insulin production. The objectives are therefore to assess parameters of beta cell s...
What is the current status of trial NCT02372253?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2015-02. Estimated completion is 2019-12.
What conditions does trial NCT02372253 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT02372253?
The interventions under investigation include: Placebo (DRUG), Verapamil (DRUG).
Who is sponsoring clinical trial NCT02372253?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02372253 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
RECRUITING · Phase 2
-
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
RECRUITING · Phase 2
-
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
Probiotics in Newly Diagnosed T1D
ACTIVE NOT RECRUITING · Phase 2
-
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.